🩺 Control Diabetes the Right Way

Managing diabetes needs more than just medicines — it requires a balanced lifestyle and proper medical care.

Take control today for a healthier tomorrow. 💙
Visit Shraddha Hospital for comprehensive diabetes care.

#DiabetesCare #BloodSugarControl

A #TextMessaging #mhealth–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin both lower blood sugar, but while insulin puts people at risk of hypoglycemia and weight gain, GLP-1 RAs do not. In addition, GLP-1 RAs have added cardiometabolic and renal benefits. For these reasons, when possible, many primary care providers prefer their patients with type 2 diabetes to be from basal insulin to a GLP-1 RA. This transition process can be labor intensive, requiring multiple dosing adjustments and a watchful eye for hypoglycemia and hyperglycemia. The Mobile Insulin Titration Intervention (MITI)–GLP1 program uses SMS #TextMessaging #mhealth–based technology to support a streamlined and supervised transition process from basal insulin to a GLP-1 RA. This program takes place at a multilingual safety-net clinic. Objective: Our objectives were to assess program #feasibility and acceptability to determine whether the intervention was doable, practical, and worthy of further investigation via a larger controlled trial. Preliminary clinical outcomes are also discussed in this paper. Methods: Patients were enrolled on a secure web platform that sent them a daily SMS text message asking the following: “What was your fasting blood sugar this morning?” Each weekday, texted responses containing patients’ fasting blood sugar levels were checked for alarm values, and once weekly, patients were called and advised on whether and how to lower their basal insulin and increase their GLP-1 RA dose. The program was co-run by general internal medicine physicians and nurses and continued until the patient had their insulin stopped completely and/or their GLP-1 RA dose reached the maximum, or 16 weeks elapsed. All enrolled patients were included in the analyses. Results: A total of 72 patients completed the pilot program. #feasibility and acceptability were high. Of 3671 SMS text messages sent by the program, 3520 (95.89%) received a response from patients. Of 719 cumulative weeks in which Thursday titration phone calls were attempted, successful connections with patients were made in 649 (90.26%) instances. Preliminary clinical outcomes were promising. Insulin doses were meaningfully reduced (55/72, 76.39% had their basal insulin reduced by at least 50%; 45/72, 62.5% had their insulin stopped completely). GLP-1 RA doses were meaningfully increased (64/72, 88.89% had their GLP-1 RA dose increased by ≥1 level; 45/72, 62.5% were discharged on the maximum dose of their GLP-1 RA). There was minimal hypoglycemia (5/3520, 0.14% of the SMS text messages reported a value of 400 mg/dL). Conclusions: A general internal medicine–run MITI-GLP1 pilot program using SMS #TextMessaging #mhealth and interdisciplinary teamwork between internists and nurses is a feasible and acceptable intervention for safely and effectively transitioning people with well-controlled type 2 diabetes away from basal insulin and toward a GLP-1 RA.

JMIR Formative Res: A #TextMessaging #mhealth–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study #DiabetesCare #GLP1RA #TextMessaging #mHealth #Insulin

🌍 The registration for #ISPAD2026 is now open! It will take place in Rio de Janeiro, Brazil 🇧🇷 from November 4–7, 2026.

⏰ Early registration deadline: July 16, 2026 (23:45 CET)

Don’t miss out, register early here: https://loom.ly/xkAylRs

#PediatricDiabetes #DiabetesCare

InsuLeaf®| USA | Official Website | Blood Sugar Supplement Looking for InsuLeaf® in the USA? Visit the official website for natural blood sugar support, real customer reviews, pricing, and secure checkout.

InsuLeaf® Reviews 2026 – Blood Sugar Support or Hype?
insuleaff.com
#InsuLeaf #BloodSugarSupport #DiabetesCare #NaturalHealth #SupplementReview

How to Find the Top Diabetologist Near Me - Diabetes Care Maintaining a healthy lifestyle, preventing complications, and improving overall quality of life. If you’ve ever searched for a “top diabetologist near me,”

How to Find the Top Diabetologist Near Me: A Complete Guide for Better Diabetes Care
If you've ever searched for a "top diabetologist near me," it likely means you're looking for expert care you can trust.
thestarbiznews.com/how-to-find-...
#Diabetologist #DiabetesCare #FindADoctor #TopDoctor

Blood Glucose Monitoring Awareness Course

🩸 Blood Glucose Monitoring Awareness
Accurate blood glucose monitoring is essential for safe and effective diabetes management across all healthcare settings. CPD accredited training for safer care.
#DiabetesCare #PatientSafety #CPD

13th International Endocrinology and Diabetes - Vydya Health - Find Providers, Products. Join us for the 13th International Conference on Endocrinology & Diabetes, scheduled for April 06-08, 2026, in Rome, Italy. Theme: “Innovations in

13th International Conference on Endocrinology and Diabetes
April 06-08, 2026
Rome, Italy

www.vydya.com/events/13th-...

#Endocrinology #Diabetes #DiabetesCare #ClinicalEndocrinology
#MedicalConference

🌍 The registration for #ISPAD2026 is now open! It will take place in Rio de Janeiro, Brazil 🇧🇷 from November 4–7, 2026.

⏰ Early registration deadline: July 16, 2026 (23:45 CET)

Don’t miss out, register early here: https://loom.ly/xkAylRs

#PediatricDiabetes #DiabetesCare

Diabetologist Perception on Diabetes Treatments (US & EU, 2026) Diabetologist insights on diabetes treatments in the US & EU (2026), covering GLP-1, SGLT2, adoption trends, key drivers, barriers, and future outlook.

A new case study reveals how diabetologists are shifting toward next-generation therapies in diabetes care. GLP-1 and dual agonists are gaining strong traction, while triple therapies are generating significant interest.

Explore more insights:
www.sperresearch.com/Case-Studies...

#DiabetesCare

6 Healthy Indian Millet Recipes for Weight Loss & Blood Sugar Support (Low GI 2026 Guide) - October 11, 2025 March 22nd, 2026 Bibhu Ranjan Mund, MPH Discover 6 healthy Indian millet recipes including ragi laddu, little millet upma and foxtail millet kheer. High-fiber, gluten-free and diabetic-friendly meal

Millets for Weight Loss & Blood Sugar Control
Struggling with weight or sugar levels?

Switch to millets 👇
✔️ Low glycemic index
✔️ Keeps you full longer
✔️ Reduces cravings
Healthy eating made simple
#WeightLoss #DiabetesCare #Millets
healthhom.com/healthy-indi...

Advanced autologous stem cell treatment for diabetes in Japan blends science and hope. 

www.placidway.com/article/6818/Advanced-Au...

#StemCellResearch #DiabetesCare #RegenerativeMedicine

Awiqli (Insulin Icodec) 3 ml Pen

FDA approval of Awiqli gives adults with type 2 diabetes the first once-weekly basal insulin option in the U.S., reducing injections from daily to weekly.

jcst2d.com/index.php/ne...

#Type2Diabetes #DiabetesCare #Insulin

🍶 Kawal gula darah dengan rasa sedap! 💙
NESTLE NUTREN GLUCOBALANCE I – susu khas untuk penghidap diabetes, 800g penuh nutrisi seimbang ✅

Jom cuba sekarang 👉 s.shopee.com.my/5q3k7zbnUo

#DiabetesCare #NutrenGlucobalance #HealthyLiving #SusuDiabetes #ShopeeMY #TrendingNow #NutritionMatters

Today, on American Diabetes Association Alert Day, we highlight the importance of early detection and monitoring of diabetes-related complications. Auto Hematology Analyzer LMHA-A902 offers advanced blood analysis, empowering healthcare professionals to provide effective care and improve patient outcomes.

American Diabetes Association Alert Day | March 24

www.labmate.com/automatic-he...

Marking American Diabetes Association Alert Day with the Auto Hematology Analyzer LMHA-A902 for advanced blood analysis and better diabetes care.

#Labmate #HematologyAnalyzer #DiabetesAlertDay #DiabetesCare

India Set To Launch Low-Cost Ozempic Copies As Patents Expire - IndiaWest News India Set To Launch Low-Cost Ozempic Copies As Patents Expire.

India Set To Launch Low-Cost Ozempic Copies As Patents Expire

Full Story: indiawest.com/india-set-to...

#OzempicIndia #Semaglutide #GenericDrugs #IndianPharma #AffordableMedicine #DiabetesCare #WeightLossDrugs

A new study finds even brief breaks from GLP-1 medications can increase the risk of heart attack, stroke, and death—highlighting the importance of staying on treatment.
youtu.be/Bx3hOlEcUOQ

#GLP1 #Semaglutide #DiabetesCare #HeartHealth #CardiovascularRisk #WeightLossDrugs

HCP Perspectives on Metabolic Diseases | US & EU Survey Insights from 50 HCPs across US & EU on metabolic diseases, treatment challenges, GLP-1 adoption, and patient outcomes in diabetes and obesity care.

Metabolic diseases are rising rapidly across the US and Europe, with over 90% of healthcare professionals reporting high prevalence.

Read the full case study:
www.sperresearch.com/Case-Studies...

#Healthcare #MetabolicDiseases #DiabetesCare #Obesity #GLP1 #SGLT2 #PharmaInsights #MarketResearch

Blood Glucose Monitoring Awareness Course

🩸 Blood Glucose Monitoring Awareness
Accurate blood glucose monitoring is essential for safe and effective diabetes management across all healthcare settings. CPD accredited training for safer care.
#DiabetesCare #PatientSafety #CPD

mHealth Intervention to Promote Nonexercise Physical Activity in Patients With Type 2 Diabetes: Secondary Analysis and Implementation Study Background: Physical activity (PA) has an important role in the prevention and treatment of type 2 diabetes (T2D). Interventions with mobile-based technology (mobile health [mHealth]) seem promising in PA promotion, but their behavioral framework is often vague, and the implementation is seldom reported. Objective: This paper examines perceived behavior change needs and implementation of an mHealth approach in increasing nonexercise PA in patients with T2D. Methods: A 3-arm mHealth intervention was conducted in primary care. Information on perceived behavior change needs was collected with a modified capability, opportunity, motivation—behavior (COM-B) questionnaire before the intervention from a separate sample of patients with T2D (n=25) and at the intervention baseline (n=119). Implementation evaluation focused on the fidelity and acceptability of the main arm of the intervention (n=39), which included 24-hour accelerometer use, a smartphone app with personal feedback, a PA leaflet, a YouTube video on walking, and individual counseling with 3 face-to-face sessions and 4 telephone contacts. Data on fidelity were accumulated during the intervention through counseling cards and cloud computing. Data on acceptability were collected with a questionnaire at the end of the intervention (Likert scale from 1 to 5). Data analysis was mainly descriptive. Results: The participants’ responses revealed 3 items in capability and 2 in motivation, which stood out as perceived behavior change needs. Moreover, the main intervention arm showed good fidelity (eg, face-to-face sessions: 112/117, 96% and telephone contacts completed: 145/156, 93%; mean weekly accelerometer use 54%; ranging from 80% to 17% during the intervention) and acceptability (mean score ranging from 3.8 to 4.8), although some challenges were also experienced, especially in cloud-computed feedback and accelerometer-app use. Conclusions: The findings on behavior change needs call for additional research since no comparable studies were found. In addition, the explanatory value of the COM-B model and the psychometric properties of the COM-B questionnaire deserve further attention. The main intervention arm seemed applicable to clinical practice. However, the challenges discovered underscore the importance of pretesting technology-based approaches in patients with T2D. Trial Registration: ClinicalTrials.gov NCT04587414; https://clinicaltrials.gov/study/NCT04587414

JMIR Formative Res: mHealth Intervention to Promote Nonexercise Physical Activity in Patients With Type 2 Diabetes: Secondary Analysis and Implementation Study #mHealth #Type2Diabetes #PhysicalActivity #HealthTech #DiabetesCare

Personalized Glucose Management With AI: Pilot Study Using a Multiarmed Bandit Approach Background: Personalized behavioral recommendations through mobile apps have proven effective in preventing serious chronic diseases such as diabetes. Recent studies have primarily focused on optimizing personalized recommendations using reinforcement learning. However, the main problem with these approaches is that they focus on behavioral changes and overlook clinical outcomes. Objective: This study aimed to propose a method for online planning of dietary and exercise recommendations to optimize postprandial glucose levels through behavioral changes directly. Methods: The proposed method is a multiarmed bandit based on a two-stage reward prediction model, where an action is a combination of the total carbohydrate intake and postprandial walking duration, and the reward is the reduction in postprandial glucose levels. We implemented the prediction of the reward for each action based on the predicted behavioral responses to an action, and subsequently, the postprandial glycemic response. Results: In a simulation experiment, we demonstrated that the proposed online algorithm can significantly improve postprandial glucose levels with personalized recommendations, compared to the randomized policy. Furthermore, we conducted a small real-world experiment with a simplified proposed method involving a single update of the recommendation policy into a personalized one. For 6 participants, compared to the randomized policy, we observed a 23% improvement, on average, in actual glucose responses along with the behavioral adherence to the recommendations concerning carbohydrate intake and postprandial walking. Conclusions: The preliminary effectiveness of the proposed method was demonstrated from both the simulation experiment and the small real-world experiment. However, further longitudinal real-world experiments in patients with diabetes are needed to validate and generalize the findings.

JMIR Formative Res: Personalized Glucose Management With AI: Pilot Study Using a Multiarmed Bandit Approach #GlucoseManagement #DiabetesCare #AIinHealthcare #PersonalizedMedicine #HealthTech

PSWs are often the first to notice early signs of diabetic foot complications.

Best Foot Forward is a free online CAPE training that helps PSWs and other unregulated care providers strengthen early detection, prevention, and communication skills.

Learn more:
capelearning.ca
#PSW #DiabetesCare

WTF Wire

Glucose monitor recall linked to 7 deaths raises alarm as faulty Abbott sensors produce dangerous blood sugar readings.

#WTFWire, #GlucoseMonitor, #MedicalDeviceRecall, #HealthAlert, #DiabetesCare, #BloodSugarMonitor, #AbbottRecall, #PatientSafety, #HealthcareNews

www.wtfwire.com/health/gluco...

Amada Senior Care infographic on diabetes care for seniors: Blue background with icons including clipboard, blood drop, glucometer showing 5.9, insulin vial, syringe, pills, and pill bottle. Title: 'Diabetes Care: Supporting Seniors with Confidence' and subtitle 'A Guide to Daily Management and Safety for Seniors with Diabetes'. Text: 'Learn how caregivers help prevent complications and ensure a better quality of life.' Amada logo with heart/hand icon at top right.

Caregivers support seniors with diabetes through daily management: blood sugar monitoring, meal timing, med reminders, foot checks & symptom watch—to prevent complications & improve quality of life.

Blog: www.amadaseniorcare.com/2026/03/how-... ❤️

#DiabetesCare #AmadaSeniorCare #AmadaTracy

RE.DOCTOR Digital Biomarker of Diabetes RE.DOCTOR Vitals: a cutting-edge remote health monitoring solution that leverages the power of digital biomarkers to detect early signs of diabetes.

🏥 Clinicians: Imagine receiving real-time glucose trends from patients — without them stepping into the clinic. RE.DOCTOR integrates with EMRs to deliver AI-processed biomarker data.
📚 Dive deeper:
re.doctor/re-doctor-di...
#Telehealth #DiabetesCare #EMRIntegration #DigitalHealth #AIHealthcare

Ozempic Weight Loss Injections in Harrow (London). Cosmetologists Ozempic Weight Loss Injections in Harrow Questions? Call Us Now: On 020 8863 1554 In the realm of weight management, it’s essential to...

Ozempic Weight Loss Injections
need-a-pro.com/en/category/...

#Ozempic #Mounjaro #Wegovy #Semaglutide #Weightlossmedication #Weightloss #Diabetestreatment #Diabetescare #Injectablemedication #WeightLossJourney #FatJab

Four-panel infographic on Type 2 Diabetes research from the METSIM cohort. Panel A details the cohort statistics with a table. Panel B shows a graph of plasma metabolites characterization, distinguishing groups with colors. Panel C, titled "Mediation Effects of Metabolites," includes an image of a microscope, beaker, and test tube. Panel D features a graph on "Incident T2D Predictive Models" illustrating ROC curves.

A large-scale metabolomic study identified 193 plasma biomarkers for T2D, advancing understanding of T2D pathophysiology & prediction. #DiabetesCare #T2D

Read here ➡️ doi.org/10.2337/dc25-2201

Diabetes may impact the heart and kidneys silently. Our Diabetic Profile + Microalbumin (10 tests) for AED 100 helps assess blood sugar, cholesterol, and kidney health. Consult our General Practitioner for timely evaluation.

#NationalHospitalAbuDhabi #DiabetesCare

Can diabetics fast safely this Ramadan?

Medical assessment matters. Never adjust insulin without professional advice.

Book your consult at National Hospital Abu Dhabi
Where Excellence in Healthcare Is Found

#NationalHospitalAbuDhabi #RamadanHealth #DiabetesCare

New oral diabetes pill shows stronger blood sugar control and weight loss, signaling a shift in patient-friendly treatments.

vist.ly/4tg8u

#longevity #DiabetesCare #MetabolicHealth #GLP1 #PharmaInnovation #ClinicalResearch #WeightManagement

RE.DOCTOR Vitals offers a clinically meaningful answer. By capturing key cardiovascular and autonomic digital biomarkers — including reduced HRV, elevated resting heart rate, and ANS indicators — it identifies early metabolic red flags before symptoms emerge. ✅ Non-invasive ✅ Real-time results ✅ Smartphone-based ✅ Scalable for telehealth This is the future of preventive diabetes care. 👉 https://re.doctor/re-doctor-digital-biomarker-of-diabetes/ #DiabetesCare #PreventiveMedicine #DigitalBiomarkers #REDOCTORVitals #Telehealth #HealthcareInnovation #Type2Diabetes #DiabetesScreening #mHealth

RE.DOCTOR Vitals offers a clinically meaningful answer.

✅ Non-invasive ✅ Real-time results ✅ Smartphone-based ✅ Scalable for telehealth

This is the future of preventive diabetes care.

👉 re.doctor/re-doctor-di...

#DiabetesCare #PreventiveMedicine #DigitalBiomarkers